| Primary Investigator | Funding Agency | Grant Number | Start Date | End Date | Project Title | Dir Cost | Tot Cost | % | Prog Dir | Prog Tot |
|---|---|---|---|---|---|---|---|---|---|---|
| Tyler Curiel | Food and Drug Administration | 7R01FD003118-02 | 3/15/2007 12:00:00 AM | 3/14/2009 12:00:00 AM | Phase II trial of ONTAK to treat ovarian cancer under BB-IND-12345 | 262757 | 350000 | 100 | 262757 | 350000 |
| Tyler Curiel | Fannie E. Rippel Foundation | 1/1/2008 12:00:00 AM | 1/7/2009 12:00:00 AM | Regulatory T cells in ovarian cancer: biology and therapeutic potential | 125000 | 125000 | 100 | 125000 | 125000 | |
| Francis Giles | NCI | 6U01CA069853-14 | 12/17/2007 12:00:00 AM | 2/28/2009 12:00:00 AM | Phase I clinical trials of anti-cancer agents | 126293 | 179544 | 100 | 126293 | 179544 |
| Francis Giles | DOD | W81XWH-08-2-0036 | 1/15/2007 12:00:00 AM | 8/14/2009 12:00:00 AM | A Molecular Oncology Program for Biomarker Discovery | 890000 | 890000 | 100 | 890000 | 890000 |
| Susan Mooberry | NCI | 5R01 CA21138-03 | 9/30/2006 12:00:00 AM | 7/31/2011 12:00:00 AM | The taccalonolides: mechanisms of action and cellular response | 186302 | 275726 | 100 | 186302 | 275726 |
| Susan Mooberry | DOD | W81XWH-08-1-0395 | 6/1/2008 12:00:00 AM | 5/31/2011 12:00:00 AM | Discovery of new therapeutic leads for prostate cancer | 117160 | 173397 | 100 | 117160 | 173397 |
| Shou-Jiang Gao | NCI | 5R01CA124332-02 | 4/1/2007 12:00:00 AM | 1/31/2012 12:00:00 AM | Regulation of KSHV infection and replication by MAPK pathways | 190000 | 277400 | 100 | 190000 | 277400 |
| Shou-Jiang Gao | NCI | 3R01CA124332-S1 | 3/1/2008 12:00:00 AM | 2/28/2011 12:00:00 AM | Regulation of KSHV infection and replication by MAPK pathways – Supplement | 54628 | 80957 | 100 | 54628 | 80957 |
| R. Aguiar | American Society of Hematology | NA | 7/1/2007 12:00:00 AM | 6/30/2009 12:00:00 AM | Intersection of cAMP-PDE4B signals and survival pathways in beta cell lymphomas: transcriptional control and relevance for targeted therapy | 49999 | 49999 | 100 | 49999 | 49999 |
| R. Aguiar | Elsa U. Pardee Foundation | 1/1/2008 12:00:00 AM | 12/31/2008 12:00:00 AM | Interplay between JNK activity and micro RNA-155 expression in lymphomas | 107200 | 134000 | 100 | 107200 | 134000 | |
| R. Aguiar | Concern Foundation | 7/1/2008 12:00:00 AM | 6/30/2009 12:00:00 AM | Regulation of micro RNA-155 expression in lymphomas | 50000 | 50000 | 100 | 50000 | 50000 | |
| J. Agyin | NCI | 5K01CA113468-04 | 6/1/2005 12:00:00 AM | 5/31/2010 12:00:00 AM | Bone-seeking proteasome inhibitors for myeloma | 135195 | 140240 | 100 | 135195 | 140240 |
| A. Bao | Susan G. Komen Breast Cancer Foundation | BCTR070169 | 9/24/2007 12:00:00 AM | 9/23/2009 12:00:00 AM | Breast cancer brachytherapy using nanoparticle-carried therapeutic radionuclides | 120449 | 150561 | 100 | 120449 | 150561 |
| G. Fields | NCI | 2R01CA098799-06 | 4/1/2008 12:00:00 AM | 3/31/2013 12:00:00 AM | Mechanism and inhibition of collagenolytic activity | 218530 | 302565 | 100 | 218530 | 302565 |
| G. Fields | NIH | 5R01EB000289-08 | 8/25/2005 12:00:00 AM | 6/30/2009 12:00:00 AM | Peptide-amphiphile biomimetics for targeted therapies | 191105 | 234448 | 100 | 191105 | 234448 |
| J. Freeman | VA-MERIT | 3/1/2008 12:00:00 AM | 2/28/2011 12:00:00 AM | Role of RON kinase in pancreatic cancer | 189000 | 189000 | 100 | 189000 | 189000 | |
| J. Freeman | NCI | 5R21CA125713-02 | 5/11/2007 12:00:00 AM | 4/30/2009 12:00:00 AM | Role of ErbB/STAT3 in the establishment and progression of pancreatic cancer | 140000 | 204400 | 100 | 140000 | 204400 |
| J. Freeman | VA Merit Award | 3/1/2008 12:00:00 AM | 2/28/2011 12:00:00 AM | Role of RON kinase in pancreatic cancer | 189000 | 189000 | 100 | 189000 | 189000 | |
| G. Fullerton | NIH | 5T32EB000817-05 | 9/1/2004 12:00:00 AM | 8/31/2009 12:00:00 AM | Multidisciplinary training program in human imaging | 233494 | 250697 | 100 | 233494 | 250697 |
| R. Ghosh | NCI | 1R21 CA125719-01 | 6/1/2008 12:00:00 AM | 5/31/2010 12:00:00 AM | Role of E2F1 in eugenol-mediated anti-proliferative activity in melanoma cells | 135000 | 195480 | 100 | 135000 | 195480 |
| R. Ghosh | NCI | 1R03 CA136058-01 | 7/1/2008 12:00:00 AM | 6/30/2010 12:00:00 AM | Capsaicin for chemoprevention of transition cell carcinoma of the bladder | 50000 | 74000 | 100 | 50000 | 74000 |
| A. Hinck | NIH | 5R01GM058670-07 | 9/1/1999 12:00:00 AM | 8/31/2010 12:00:00 AM | Ligand-receptor interactions in the TGF-b superfamily | 173639 | 253513 | 100 | 173639 | 253513 |
| A. Hinck | Welch Foundation | AQ-1431 | 5/1/2008 12:00:00 AM | 4/30/2011 12:00:00 AM | Ligand-receptor interactions in the TGF-b superfamily | 50000 | 50000 | 100 | 50000 | 50000 |
| C. Keller | NCI | 1R01CA133229-01 | 4/22/2008 12:00:00 AM | 1/31/2013 12:00:00 AM | Therapeutic targets in alveolar rhabdomyosarcoma | 207500 | 307100 | 100 | 207500 | 307100 |
| C. Keller | Numira Biosciences Inc | 8/1/2007 12:00:00 AM | 2/28/2009 12:00:00 AM | Multi-platform (multiplat) reporter system | 299745 | 359659 | 100 | 299745 | 359659 | |
| C. Keller | Amschwand Sarcoma Cancer Foundation | 12/15/2007 12:00:00 AM | 12/14/2008 12:00:00 AM | Role of platelet-derived growth factor receptor a in rhabdomyosarcoma | 25000 | 25000 | 100 | 25000 | 25000 | |
| C. Keller | Alex’s Lemonade Stand | 7/1/2008 12:00:00 AM | 6/30/2009 12:00:00 AM | Therapeutics in Ovo | 97875 | 97875 | 100 | 97875 | 97875 | |
| A. Kumar | DOD | W81XWH-04-1-0275 | 11/17/2005 12:00:00 AM | 2/28/2009 12:00:00 AM | Antioxidant prophylaxis in the prevention of prostatic epithelial neoplasia | 57025 | 83226 | 100 | 57025 | 83226 |
| A. Kumar | ACS | 04-169-01 | 7/1/2005 12:00:00 AM | 6/30/2009 12:00:00 AM | 2-Methoxyestradiol in prostate cancer management: mechanism of action | 150000 | 180000 | 100 | 150000 | 180000 |
| A. Kumar | NCI | R01 CA135451-01 | 7/1/2008 12:00:00 AM | 5/31/2013 12:00:00 AM | Targeting flip for prostate cancer prevention | 207500 | 303116 | 100 | 207500 | 303116 |
| R. Ludueña | DOD | W81XWH-05-1-0238 | 1/31/2005 12:00:00 AM | 2/28/2009 12:00:00 AM | Development of a novel chemotherapeutic approach to breast cancer | 72172 | 97239 | 100 | 72172 | 97239 |
| R. Ludueña | Ziopharm Company | 4/1/2008 12:00:00 AM | 10/31/2008 12:00:00 AM | Interaction of indibulin with tubulin isotypes | 27667 | 35589 | 100 | 27667 | 35589 | |
| M. Natarajan | NCI | 5R01-CA112175-03 | 12/12/2005 12:00:00 AM | 11/30/2009 12:00:00 AM | Enhanced apoptosis by targeting protein redox status | 127444 | 174209 | 100 | 127444 | 174209 |
| B. Oyajobi | NCI | 5K01-CA104180-05 | 5/26/2004 12:00:00 AM | 4/30/2009 12:00:00 AM | NF-kB in myeloma cell growth and survival in vivo | 146750 | 158490 | 100 | 146750 | 158490 |
| B. Oyajobi | NCI | 5P0-CA040035-19 | 9/1/2006 12:00:00 AM | 8/31/2011 12:00:00 AM | Effects of tumors on the skeleton (Project 2) | 70693 | 103212 | 100 | 70693 | 103212 |
| S. Padalecki | DOD | W81XWH-08-1-0287 | 6/1/2008 12:00:00 AM | 5/31/2011 12:00:00 AM | Hyaluronic acid as a target for intervention in prostate cancer metastases | 125000 | 182500 | 100 | 125000 | 182500 |
| L. Penalva | NIH | U01HG004571-01 | 9/27/2007 12:00:00 AM | 6/30/2009 12:00:00 AM | Comprehensive identification of encode in the human genome | 119835 | 174959 | 100 | 119835 | 174959 |
| L. Sun | NCI | 5P01CA040035 | 9/1/2007 12:00:00 AM | 8/31/2009 12:00:00 AM | Effects of tumors on the skeleton (Project #3) | 86073 | 125667 | 100 | 86073 | 125667 |
| L. Sun | NCI | 2R01 CA75253-11A1 | 7/15/1997 12:00:00 AM | 7/31/2009 12:00:00 AM | Targeting transforming growth factor beta for cancer treatment | 149951 | 218928 | 100 | 149951 | 218928 |
| L. Sun | NCI | 5R01CA079683-09A1 | 1/1/1999 12:00:00 AM | 5/31/2009 12:00:00 AM | TGF beta receptor and tumor progression | 149338 | 221020 | 100 | 149338 | 221020 |
| Z. Yuan | NCI | 1R01CA125144-01A2 | 7/1/2008 12:00:00 AM | 7/31/2013 12:00:00 AM | The role of Beclin 1/class III PI-3 kinase and p53 in breast cancer | 250000 | 370000 | 100 | 250000 | 370000 |
| Z. Yuan | NCI | 5R01CA085679-08 | 6/1/2008 12:00:00 AM | 5/31/2009 12:00:00 AM | Molecular basis of p3-induction to DNA damage | 118785 | 175802 | 100 | 118785 | 175802 |